Pharmacokinetics of ceftriaxone after a single dose of 50 or 75 mg/kg were determined in 30 pediatric patients with bacterial meningitis. Data for doses of 50 and 75 mg/kg, respectively, were as follows (mean ± standard deviation): maximum plasma concentrations, 230 ± 64 and 295 ± 76 ,ug/ml; elimination rate constant, 0.14 ± 0.06 and 0.14 ± 0.04 h-1; harmonic elimination half-life, 5 infants, aged 6 weeks to 2 years, who were receiving conventional therapy for documented bacterial meningitis at Arkansas Children's Hospital, Little Rock. Written informed consent was obtained from the parents of all participants. Between days 2 and 5 of therapy, when infection was judged to be under adequate control, and without alteration of the antimicrobial regimen, a single dose of ceftriaxone was administered intravenously over a 10-min period. The study was randomized so that half of the patients received 50 mg/kg and half received 75 mg/kg for this one infusion.
distribution, 382 ± 129 and 387 ± 56 ml/kg; mean concentration in cerebrospinal fluid 1 to 6 h after infusion, 5.4 and 6.4 ,ug/ml. A dosage schedule of 50 mg/kg every 12 h for bacterial meningitis caused by susceptible organisms is suggested for pediatric patients over 7 days of age.
Newer 1-lactam antibiotics have been considered as an alternative to the current therapy for bacterial meningitis. There are features unique to these agents which make them particularly attractive, primarily their excellent penetration into cerebrospinal fluid (CSF), a broad spectrum of bactericidal activity including most enteric organisms and 3-lactamase-producing Haemophilus influenzae, and relatively rare toxicity. Ceftriaxone offers additional advantages over other 3-lactam antibiotics in its activity against group B streptococci and relatively long halflife.
The present study was designed to examine ceftriaxone pharmacokinetics after a single intravenous dose. Safety and tolerance were also evaluated.
MATERIAULS AND METHODS
Patients and study deign. The study population included five full-term neonates, 8 to 21 days, and 25 infants, aged 6 weeks to 2 years, who were receiving conventional therapy for documented bacterial meningitis at Arkansas Children's Hospital, Little Rock. Written informed consent was obtained from the parents of all participants. Between days 2 and 5 of therapy, when infection was judged to be under adequate control, and without alteration of the antimicrobial regimen, a single dose of ceftriaxone was administered intravenously over a 10-min period. The study was randomized so that half of the patients received 50 mg/kg and half received 75 mg/kg for this one infusion.
Plasma samples were obtained just before infusion and at 15, 30, and 60 min and 2, 4, 6, and 10 h after infusion. A lumbar puncture was performed 1 to 6 h after drug administration, and a sample of CSF was obtained for analysis of ceftriaxone concentration.
Susceptibility studies. Mean inhibitory concentrations (MICs) of ceftriaxone for each pathogen were determined by standard microtiter broth dilution (6) . An inoculum of 105 organisms per ml in logarithmic growth phase was introduced into wells containing appropriate nutrients for that organism and serial dilutions of ceftriaxone. Cftriaxone concentrations. Plasma and CSF concentrations of ceftriaxone were analyzed by highpressure liquid chromatographic techniques (9) . To monitor ceftriaxone levels on a daily basis for patients receiving this investigational antibiotic, microbiological methodology was employed; briefly, this was a standard agar well diffusion assay in which susceptible Escherichia coli is used after dilution of the specimen with pooled plasma (1).
Pharmacokinetic determinations. The elimination rate constant, 1, was determined from the regression Clinical and laboratory studies. Patients were carefully monitored for adverse reactions during infusion by one of the investigators and followed during the duration of hospitalization. In addition, laboratory parameters for bone marrow, renal, or hepatic toxicity were obtained preinfusion and at 2 and 4 days. These included CBC, blood urea nitrogen, creatinine, urinal-192 STEELE ET AL. Table 2 and Fig. 1. ANTIMICROB. AGENTS CHEMOTHER.
Most importantly, concentrations in CSF were usually 10 to 100 times greater than the MIC for recovered bacteria. The measured levels of ceftriaxone in the two infants with S. aureus were two-to threefold higher than the MIC for those organisms. Other exceptions included three resistant organisms already described.
Ceftriaxone administered intravenously over a 10-min period was well tolerated by infants and neonates, with no local or systemic reactions observed. There were no changes in laboratory parameters used to assess bone marrow, renal, or hepatic toxicity.
CSF drug concentrations are presented in Table 2 simply as the mean for all samples obtained; the wide variation in the time that CSF was obtained (1 to 6 h) prevents a full statistical analysis of penetration into CSF for these study subjects. The CSF-to-plasma concentration ratio ranged from 1.8 to 24.6% after a single dose. Results for individual patients are presented in Fig. 2 Preliminary studies for the treatment of bacterial meningitis in neonates, infants, and children have been published (4). Clinical efficacy and tolerance studies in adults with serious bacterial infections have recently been published and have established ceftriaxone as an agent with a high degree of efficacy and a low incidence of toxicity (3, 7) . These reports support its selection as single drug therapy for a variety of clinical presentations.
The present studies have focused on aspects of meningitis therapy in children primarily to establish dosage recommendations for future treatment protocols and to examine CSF drug levels relative to susceptibility of degree that should provide adequate levels to treat the usual bacterial causes of meningitis. The measured plasma half-life was longer than those of other cephalosporins and investigational P-lactam antibiotics, ensuring a greater duration of bactericidal activity for individual doses. These initial pharmacokinetic data establish a tentative dosage schedule of 50 mg/kg every 12 h for the treatment of meningitis in pediatric patients over 7 days of age.
